Fig. 4From: HELLS serves as a poor prognostic biomarker and its downregulation reserves the malignant phenotype in pancreatic cancerCorrelation between the mRNA expression of SMARCAs and tumor stages in patients with pancreatic cancer (GEPIA). A–C The expression levels of SMARCA1, SMARCA2, and SMARCA3 were remarkably correlated with the tumor stages (P < 0.05); D–H The expression levels of SMARCA4, SMARCA5, HELLS, SMARCAD1, and SMARCAL1 did not differ significantly (P > 0.05) Back to article page